US Stock MarketDetailed Quotes
IPA ImmunoPrecise Antibodies
- 0.980
- -0.010-1.01%
Close Jul 10 16:00 ET
25.79MMarket Cap-2344P/E (TTM)
1.000High0.951Low28.81KVolume0.980Open0.990Pre Close27.98KTurnover0.13%Turnover RatioLossP/E (Static)26.32MShares2.94052wk High0.71P/B22.34MFloat Cap0.94052wk Low--Dividend TTM22.79MShs Float33.340Historical High--Div YieldTTM5.00%Amplitude0.940Historical Low0.971Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
ImmunoPrecise Antibodies Stock Forum
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
ImmunoPrecise Antibodies (IPA) announced a strategic collaboration between its subsidiary, BioStrand, and PGxAI to develop an AI model for pharmacogenomics, leveraging BioStrand's LENSai technology. This partnership aims to enhance precision medicine by integrating AI with vast genomic data to improve pa...
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a company in AI-driven biotherapeutic research and technology, has announced the immediate commercial release of its subsidiary BioStrand’s new software offering, LENSai API. This advanced software solution,...
Biostrand, Immunoprecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software With Customizable Interface for AI-Driven Drug Discovery
NEWS
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
VICTORIA, BC / ACCESSWIRE / April 22, 2024 /ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, has recently announced an expansion of its already successful LENSai TMPlatform. LENSai, which is run by the company's subsidiary, BioStrand, provides a ...
NEWS
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
loading...
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga Co's Subsidiary BioStrand And InterSystems Announce A Collaboration For AI-Driven Healthcare Applications
EXCLUSIVE: ImmunoPrecise Antibodies Tells Benzinga 'This Collaboration Integrates the New Vector Search Capability of the InterSystems IRIS Data Platform With IPA's Subsidiary BioStrand's LENS Platform for AI-driven Applications in Healthcare'
Dow Jones· 4 mins ago
No comment yet